fluorouracil has been researched along with platinum in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.95) | 18.7374 |
| 1990's | 11 (12.50) | 18.2507 |
| 2000's | 13 (14.77) | 29.6817 |
| 2010's | 29 (32.95) | 24.3611 |
| 2020's | 28 (31.82) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, LM; Glae, GR; Meischen, SJ; Smith, AB; Walker, EM | 1 |
| Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M | 1 |
| Allegra, C; Jacob, J; Ozols, RF; Reed, E; Young, RC | 1 |
| Egorin, MJ; Haraf, DJ; Mick, R; Moormeier, JA; Ratain, MJ; Vokes, EE; Weichselbaum, RR | 1 |
| DeGregorio, MW; Denham, A; Gandara, DR; Perez, EA; Wiebe, VJ | 1 |
| Atkinson, N; Castellanos, AM; Choksi, AJ; Dimery, IW; Felder, TB; Hong, WK; McCarthy, K; Newman, RA; Paredes, J; Robbins, KT | 1 |
| Gang, M; Kline, I; Sirica, AE; Venditti, JM; Woodman, RJ | 1 |
| deKernion, JB; Persky, L; Rose, D; Soloway, MS | 1 |
| Asfaw, I; Buroker, T; Dindogru, A; Franklin, R; Hoschner, D; Knechtges, T; Leichman, L; Loh, JJ; Miller, P; Pietruk, T; Rosenberg, JC; Seydel, H; Steiger, Z; Torres, A; Vaishamapayan, G; Vaitkevicius, V; Wilson, RF | 1 |
| Akman, S; Doroshow, JH; Hamasaki, V; Leong, L; Margolin, K; Morgan, R; Newman, E; Raschko, J; Somlo, G; Womack, E | 1 |
| Fukushima, M; Hashimoto, T; Ishida, F; Kawakami, K; Matsu, T; Omura, K; Osari, A; Sunohara, T; Watanabe, Y; Yasuda, T | 1 |
| Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S | 1 |
| Allain, P; Buquet-Fagot, C; Cvitkovic, E; Djelloul, S; Gespach, C; Louvet, C; Mester, J; Raymond, E | 1 |
| Ikeda, K; Ishida, K; Iwaya, T; Kawamura, H; Koeda, K; Maesawa, C; Saito, K; Sato, N; Takagane, A; Takiyama, I; Terashima, M; Yoshinari, H | 1 |
| Allain, P; Boisdron-Celle, M; Brienza, S; Cailleux, A; Cvitkovic, E; Gamelin, E; Krikorian, A; Larra, F; Lebouil, A; Robert, J; Turcant, A | 1 |
| Allain, P; Boisdron-Celle, M; Bouil, AL; Brienza, S; Cailleux, A; Cvitkovic, E; Delva, R; Gamelin, E; Krikorian, A; Larra, F; Robert, J; Turcant, A | 1 |
| Armand, JP; Cunningham, D; Kohne, CH; Misset, JL; van Cutsem, E | 1 |
| Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Adjei, AA; Bruzek, LM; Davis, JN; Erlichman, C; Kaufmann, SH | 1 |
| Kumada, K; Makuuchi, M; Midorikawa, T; Nemoto, H; Sanada, Y; Sasaya, S; Takeuchi, S; Takizawa, K; Uemichi, O; Yamaguchi, M; Yoshizawa, Y | 1 |
| Brasnu, D; Hans, S; Laccourreye, H; Laccourreye, O; Ménard, M; Veivers, D | 1 |
| Fuwa, N; Hayashi, N; Kano, M; Kawashima, M; Myojin, M; Nakamura, K; Ohnishi, H; Saijo, S; Shikama, N; Toita, T; Yamamoto, M | 1 |
| Chang, HM; Choi, SJ; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, YH; Ryu, BY | 1 |
| Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK | 1 |
| Iwazawa, T; Kanoh, T; Kimura, Y; Mizuno, H; Monden, T; Nakano, Y; Ohnishi, T; Shin, S; Shiozaki, K; Tono, T; Yano, K | 1 |
| Cao, J; Chen, Z; Li, J; Lv, F; Zuo, Y | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 1 |
| Ishibashi, K; Ishida, H; Miyazaki, T; Okada, N; Sano, M | 1 |
| Li, J; Saif, MW | 1 |
| Fareed, KR; Ilyas, M; Kaye, PV; Lobo, DN; Madhusudan, S; Parsons, SL; Soomro, IN | 1 |
| Benasso, M; Erfán, J; Hitt, R; Kawecki, A; Licitra, L; Mesia, R; Remenár, É; Rivera, F; Rottey, S; Senger, S; Störkel, S; Stroh, C; Vermorken, JB; Zabolotnyy, D | 1 |
| Kajiura, Y; Yagata, H; Yamauchi, H | 1 |
| Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Mihara, Y; Okubo, R; Takayama, T | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Kang, WK; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yi, JH; Yim, DS | 1 |
| Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Pavlidis, N | 1 |
| Blair, E; Cohen, EE; Golden, DW; Haraf, DJ; Nwizu, T; Rudra, S; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
| Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
| Dzik, C; Guindalini, RS; Mak, MP; Takahashi, TK; Testa, L | 1 |
| Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
| Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
| Chen, X; Feng, J; Guan, X; Hong, Y; Song, H; Ye, J; You, X; Zheng, P | 1 |
| Bai, Y; Chu, YP; Gong, JF; Li, J; Li, Y; Shen, L; Zhang, XT | 1 |
| Alves, MP; Avezedo, I; de Mello, RA; Dinis, J; Gerós, S; Moreira, F | 1 |
| Fang, W; Jiang, H; Mao, C; Qian, J; Xu, N; Zhang, X; Zhao, P; Zheng, Y | 1 |
| Bail, JP; Brigand, C; Collet, D; Gronnier, C; Lebreton, G; Luc, G; Mabrut, JY; Mariette, C; Meunier, B | 1 |
| Adkins, D; Aguilar, JL; Bryant, K; Chang, SC; Chen, E; Chin, S; Ernst, S; He, S; Lee, HJ; Misiukiewicz, K; Obasaju, CK; Soulières, D | 1 |
| Binder, M; Bokemeyer, C; Braig, F; Busch, CJ; Grob, T; Knecht, R; Kriegs, M; Laban, S; Schieferdecker, A; Voigtlaender, M | 1 |
| Bu, Z; Hu, Y; Ji, J; Jia, Y; Li, S; Li, Z; Miao, R; Shan, F; Wu, A; Xiao, A; Xing, X; Xing, Z; Xue, K; Zhang, L | 1 |
| Cadeddu, C; Deidda, M; Demurtas, L; Madeddu, C; Mercuro, G; Piras, A; Piscopo, G; Puzzoni, M; Scartozzi, M | 1 |
| Bozkaya, Y; Demirci, NS; Erdem, GU; Ozdemir, NY; Yazici, O; Zengin, N | 1 |
| Ahsan, H; Ali, SS; Khan, FH; Rehman, AA; Siddiqui, T; Zia, MK | 1 |
| Black-Shinn, J; Boyd, M; Chirovsky, D; Joo, S; Nadler, E | 1 |
| Beedu, SR; Godugu, D | 1 |
| Cao, Y; Chang, Q; Chen, EX; Hedley, D; Ornatsky, O; Zhang, W | 1 |
| Bouvet, M; Clary, B; Han, Q; Higuchi, T; Hoffman, RM; Park, JH; Singh, SR; Sugisawa, N; Tan, Y; Yamamoto, J; Yoon, SN; Zhao, M | 1 |
| Aprile, G; Brandi, G; Brieau, B; Casadei-Gardini, A; Dahan, L; Evesque, L; Filippi, R; Le Sourd, S; Lièvre, A; Lonardi, S; Meurisse, A; Neuzillet, C; Pointet, AL; Rousseau, B; Scartozzi, M; Silvestris, N; Tougeron, D; Vernerey, D; Vienot, A; Vivaldi, C | 1 |
| Chen, X; Ding, H; Ding, J; Luo, D; Wang, L; Wei, Y; Xiong, Y; Yi, F; Zhang, W | 1 |
| Ji, LN; Mao, ZW; Muhammad, N; Nasreen, S; Nawaz, U; Tan, CP; Wang, FX; Wang, J | 1 |
| Luo, Y; Pei, S; Xiao, Y; Xu, J; Zhu, X | 1 |
| Hwang, M; Seiwert, TY | 1 |
| Cavalieri, S; Licitra, L | 1 |
| Honma, Y; Ishiki, H; Kosaka, M | 1 |
| Auperin, A; Bourhis, J; Fraslin, A; Guigay, J; Keilholz, U; Mesia, R | 1 |
| Cortes-Bullich, A; Gonzalez-Perez, A; Lopez-Bigas, N; Muiños, F; Pich, O; Pratcorona, M | 1 |
| Demachi, K; Fujita, T; Fujiwara, H; Kojima, T; Kotani, D; Okunaka, M; Sakashita, S; Yoshino, T | 1 |
| Chen, C; Ding, SR; Glorieux, C; Huang, P; Huang, ZL; Li, H; Li, XH; Liu, SR; Tao, YL; Wang, GN; Wang, HB; Wei, YH; Wu, YF; Xia, YF; Zheng, SH | 1 |
| Crowley, JD; Hartinger, CG; Lisboa, LS; McAdam, CJ; Preston, D; Wright, LJ | 1 |
| But, B; Chan, ATC; Chappell, RJ; Cheng, AC; Choi, CW; Kwong, DLW; Lee, AWM; Lee, S; Lu, TX; Ng, WT; Ngan, RKC; Tung, S; Wong, F; Yiu, H; Yuen, KT | 1 |
| Bellile, E; Bradford, CR; Carey, TE; Casper, K; Chinn, SB; Dragovic, AF; Eisbruch, A; Jolly, S; Kupfer, R; Malloy, KM; Mierzwa, ML; Prince, ME; Shuman, AG; Spector, ME; Srinivasan, A; Stucken, C; Swiecicki, PL; Wolf, GT; Worden, FP | 1 |
| Cho, MS; Cho, SY; Huh, YJ; Lee, JH; Lee, KE | 1 |
| Hu, Y; Tang, C; Wei, X; Yuwen, D; Zhang, J; Zhang, W; Zhu, X; Zhu, Y | 1 |
| Gao, LL; Li, H; Sun, Y; Tang, YF; Zhao, Z | 1 |
| Alati, A; Bibault, JE; Charles-Nelson, A; Durdux, C; Fabiano, E; Geiss, R; Giraud, P; Housset, M; Kreps, S; Mareau, A; Méjean, A | 1 |
| Hirota, M; Kawada, J; Kawakami, H; Kii, T; Kurokawa, Y; Matsuyama, J; Nomura, M; Ohta, T; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T | 1 |
| Akimoto, T; Daiko, H; Fujita, T; Fujiwara, H; Hojo, H; Ito, R; Kojima, T; Nakamura, N; Nakamura, Y; Sunakawa, H; Yano, T; Yoshino, T | 1 |
| Guo, Z; Jia, Y; Song, R; Wu, C; Zhang, R; Zhang, S; Zhang, X; Zhao, Y | 1 |
| Enzinger, PC; Guo, H; Joo, S; Meng, Y; Qu, T; Zhang, S; Zhong, Y | 1 |
| Fujii, T; Fujimoto, Y; Gumuscu, B; Hanai, N; Hara, H; Matsumoto, K; Mitsugi, K; Nakayama, M; Nohata, N; Oridate, N; Shiga, K; Shimizu, Y; Swaby, RF; Tahara, M; Takahashi, K; Takahashi, M; Takahashi, S; Tanaka, K; Ueda, T; Yamaguchi, H; Yamazaki, T; Yasumatsu, R; Yokota, T; Yoshizaki, T | 1 |
| Li, C; Li, X; Shen, L; Wang, S; Wang, T; Zhai, J | 1 |
| Colevas, AD; Coty, J; Hara, W; Jun, M; Le, QT; Lira, R; Lu, R; McMillan, A; Pinto, H; Quon, A; Winters, E | 1 |
| Nowak, D; Quartucci, C; Rakete, S; Rooney, JPK | 1 |
| Brossart, P; Feldmann, G; Gonzalez-Carmona, MA; Jafari, A; Kalff, JC; Köksal, M; Lingohr, P; Mahn, R; Mańczak, A; Möhring, C; Monin, MB; Sadeghlar, F; Sarria, GR; Sommer, N; Strassburg, CP; Timotheou, A; Toma, M; Zhou, T | 1 |
| Bonomo, P; Borcoman, E; Cau, MC; Depenni, R; Ghi, MG; Ghiani, M; Le Tourneau, C; Leo, L; Messinger, D; Montesarchio, V; Ronzino, G; Salmio, S; Sbrana, A; Schulten, J | 1 |
11 review(s) available for fluorouracil and platinum
| Article | Year |
|---|---|
Fluorouracil and leucovorin in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Female; Fluorouracil; Humans; Leucovorin; Platinum | 1993 |
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Platinum; Quinazolines; Taxoids; Thiophenes; Topoisomerase I Inhibitors | 1999 |
A multi-institutional survey of the effectiveness of chemotherapy combined with radiotherapy for patients with nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Data Collection; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Platinum; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2004 |
Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Platinum; Receptors, Estrogen; Taxoids | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
Concurrent chemoradiotherapy comparison of taxanes and platinum versus 5-fluorouracil and platinum in nasopharyngeal carcinoma treatment.
Topics: Carcinoma; Chemoradiotherapy; Fluorouracil; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum; Taxoids; Treatment Outcome | 2014 |
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Topics: Anthracyclines; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cardiotoxicity; Fluorouracil; Heart Failure; Humans; Neoplasms; Oxidative Stress; Platinum; Stroke Volume; Taxoids; Ventricular Dysfunction, Left | 2016 |
Chemotherapeutic Drugs and Plasma Proteins: Exploring New Dimensions.
Topics: Antineoplastic Agents; Blood Proteins; Cell Survival; Cisplatin; Coordination Complexes; Fluorouracil; Humans; Neoplasms; Platinum; Ruthenium | 2018 |
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Esophagogastric Junction; Fluorouracil; Gastrointestinal Neoplasms; Humans; Neoplasm Staging; Oxonic Acid; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Fluorouracil; Humans; Leukopenia; Lung Neoplasms; Platinum; Taxoids; Thrombocytopenia | 2022 |
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvant; Esophagogastric Junction; Fluorouracil; Humans; Neoadjuvant Therapy; Network Meta-Analysis; Platinum; Stomach Neoplasms; Taxoids | 2022 |
16 trial(s) available for fluorouracil and platinum
| Article | Year |
|---|---|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Leucovorin; Lung Neoplasms; Male; Middle Aged; Platinum | 1992 |
Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Ditiocarb; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kidney; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Random Allocation | 1988 |
Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kidney; Male; Middle Aged; Platinum; Stomach Neoplasms | 1998 |
Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Platinum; Regression Analysis | 1998 |
Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Fluorouracil; Half-Life; Humans; Infusions, Intravenous; Leucovorin; Mass Spectrometry; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum; Regression Analysis; Sensitivity and Specificity | 1997 |
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Drug Administration Schedule; Endpoint Determination; Female; Fluorouracil; Humans; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Stomach Neoplasms | 2005 |
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatinine; Female; Fluorouracil; Humans; Korea; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum | 2006 |
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Fluorouracil; Gene Dosage; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Female; Fluorouracil; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Platinum; Pyrroles; Salvage Therapy; Stomach Neoplasms; Sunitinib; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Middle Aged; Paclitaxel; Platinum; Pyrimidines; Stomach Neoplasms | 2013 |
Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Middle Aged; Neutropenia; Oxonic Acid; Paclitaxel; Platinum; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemistry, Pharmaceutical; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2016 |
Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Organ Preservation; Platinum; Proto-Oncogene Proteins c-bcl-2 | 2022 |
A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Taxoids | 2022 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Fluorouracil; Head and Neck Neoplasms; Humans; Japan; Neoplasm Recurrence, Local; Platinum; Squamous Cell Carcinoma of Head and Neck | 2022 |
61 other study(ies) available for fluorouracil and platinum
| Article | Year |
|---|---|
Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents.
Topics: Animals; Cell Survival; Cisplatin; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Fluorouracil; Leukemia L1210; Mesylates; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Organometallic Compounds; Platinum; Propylamines; Vincristine | 1976 |
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Hybridization, Genetic; Hydroxyurea; Lomustine; Male; Methotrexate; Neoplasms, Experimental; Platinum; Prostatic Neoplasms; Rats | 1978 |
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Remission Induction | 1992 |
Pharmacokinetics of cisplatin in patients receiving interleukin-2-containing treatment regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Creatinine; Fluorouracil; Humans; Interleukin-2; Metabolic Clearance Rate; Neoplasms; Platinum | 1989 |
The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
Topics: Amines; Animals; Antineoplastic Agents; Azacitidine; Camptothecin; Carmustine; Chlorides; Cyclophosphamide; Cytarabine; Drug Synergism; Emetine; Fluorouracil; Ketones; Leukemia L1210; Male; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Piperazines; Platinum; Propane; Time Factors | 1973 |
Effect of chemotherapeutic agents on bladder cancer: a new animal model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamines; Disease Models, Animal; Doxorubicin; Fluorouracil; Hydroxyurea; Lomustine; Mice; Mice, Inbred C3H; Platinum; Urinary Bladder Neoplasms | 1973 |
Eradication and palliation of squamous cell carcinoma of the esophagus with chemotherapy, radiotherapy, and surgical therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagus; Female; Fluorouracil; Humans; Male; Middle Aged; Mitomycins; Platinum | 1981 |
[Pharmacokinetics and changes of reduced folate levels in tumor after administration of cisplatin].
Topics: Animals; Cisplatin; Dose-Response Relationship, Drug; Fluorouracil; Formaldehyde; Male; Platinum; Rats; Sarcoma, Yoshida; Tetrahydrofolates | 1994 |
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Mitomycin; Ovarian Neoplasms; Platinum; Salvage Therapy | 1993 |
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Thymidylate Synthase; Tumor Cells, Cultured | 1997 |
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcinoma; Cisplatin; DNA Adducts; Drug Monitoring; Female; Fluorouracil; Humans; Lymphocytes; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Platinum; Predictive Value of Tests; Saliva | 1999 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Apoptosis; Cell Cycle; Cisplatin; DNA Adducts; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Melphalan; Piperidines; Platinum; Pyridines; Tumor Cells, Cultured | 2001 |
[Tissue platinum distribution and the effect following intra-arterial injection of cisplatin to metastatic liver cancer--a case report].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Platinum; Tissue Distribution | 2001 |
Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorouracil; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasms, Second Primary; Pharyngeal Neoplasms; Platinum; Salvage Therapy | 2001 |
[FOLFOX 4 in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Routes; Female; Fluorouracil; Humans; Kidney Failure, Chronic; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Platinum; Renal Dialysis; Sigmoid Neoplasms | 2007 |
Primary small intestinal malignant tumors: survival analysis of 48 postoperative patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Platinum; Prognosis; Proportional Hazards Models; Survival Analysis | 2008 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
[Changes in peripheral neuropathy and platinum concentrations in patients undergoing surgery following modified FOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Erythrocyte Count; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Peripheral Nervous System Diseases; Platinum | 2008 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Platinum; Remission Induction; Retrospective Studies; Single-Blind Method; Stomach Neoplasms; Treatment Outcome | 2009 |
Pharmacokinetics of oxaliplatin in gastrointestinal cancer patients with malignant ascites.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ascites; Ascitic Fluid; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Platinum | 2011 |
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasms, Unknown Primary; Platinum; Prognosis; Taxoids; Treatment Outcome | 2012 |
Outcomes of induction chemotherapy followed by concurrent chemoradiation for nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Hydroxyurea; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Male; Humans; Leucovorin; Male; Organoplatinum Compounds; Palliative Care; Platinum; Seminal Vesicles | 2014 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Europe; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Grading; Platinum; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; France; Humans; Incidence; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Fluorouracil; GTP Phosphohydrolases; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Liquid Biopsy; Membrane Proteins; Mutation; Platinum; Proto-Oncogene Proteins p21(ras); ras Proteins | 2016 |
ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Platinum; Polymorphism, Single Nucleotide; Stomach Neoplasms | 2016 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorine; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Patient Safety; Platinum; Pyrimidines; Stomach Neoplasms; Taxoids; Treatment Outcome | 2018 |
Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Practice Patterns, Physicians'; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome | 2019 |
Synthesis, characterisation and anti-tumour activity of biopolymer based platinum nanoparticles and 5-fluorouracil loaded platinum nanoparticles.
Topics: Antineoplastic Agents; Biological Assay; Biopolymers; Drug Carriers; Fluorouracil; Metal Nanoparticles; Platinum | 2019 |
Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colorectal Neoplasms; Female; Fluorouracil; Heavy Metal Poisoning, Nervous System; Humans; Leucovorin; Limit of Detection; Male; Mass Spectrometry; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Platinum; Skin | 2019 |
Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carbon-Sulfur Lyases; Cell Proliferation; Colonic Neoplasms; Fluorescence; Fluorouracil; Humans; Mice, Nude; Peritoneum; Platinum; Recombinant Proteins; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Female; Fluorouracil; France; Humans; Irinotecan; Italy; Male; Middle Aged; Platinum; Prospective Studies; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Multiaction Platinum(IV) Prodrug Containing Thymidylate Synthase Inhibitor and Metabolic Modifier against Triple-Negative Breast Cancer.
Topics: Apoptosis; Cell Line, Tumor; Coordination Complexes; DNA Damage; Drug Liberation; Enzyme Inhibitors; Fluorouracil; Humans; Intracellular Space; Mitochondria; Platinum; Prodrugs; Reactive Oxygen Species; Thymidylate Synthase; Transcription, Genetic; Triple Negative Breast Neoplasms | 2020 |
Combined chemotherapy of platinum and fluorouracil promotes T cell-mediated antitumor immunity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Fluorouracil; Humans; Melanoma; Mice, Inbred C57BL; Neoplasms; NF-kappa B p50 Subunit; Oxaliplatin; Platinum; Stomach Neoplasms; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer | 2021 |
Are taxanes the future for head and neck cancer? Pragmatism in the immunotherapy era.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Platinum; Taxoids | 2021 |
Next generation platinum salt in nasopharygeal carcinoma.
Topics: Carcinoma; Chemoradiotherapy; Cisplatin; Cyclobutanes; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Organoplatinum Compounds; Platinum | 2021 |
Unresolved questions regarding the promise of the TPEx regimen.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Humans; Platinum | 2021 |
Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.
Topics: Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Humans; Platinum | 2021 |
The evolution of hematopoietic cells under cancer therapy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clonal Evolution; Clone Cells; Cohort Studies; Female; Fluorouracil; Hematopoiesis; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid; Mutagenesis; Mutation; Neoplasms, Second Primary; Platinum; Tumor Suppressor Protein p53 | 2021 |
Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Retrospective Studies | 2022 |
Treatment and Survival Outcomes Associated With Platinum Plus Low-Dose, Long-term Fluorouracil for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome | 2021 |
Heterotrimetallic Double Cavity Cages: Syntheses and Selective Guest Binding.
Topics: Crystallography, X-Ray; Fluorouracil; Magnetic Resonance Spectroscopy; Platinum | 2022 |
Exploratory Study of NPC-0501 Trial: Optimal Cisplatin Dose of Concurrent and Induction/Adjuvant Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum; Radiotherapy, Intensity-Modulated | 2022 |
Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.
Topics: Fluorouracil; Genes, Neoplasm; Humans; Mutation; Platinum; Stomach Neoplasms | 2022 |
Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer.
Topics: Biomarkers, Tumor; Fluorouracil; Humans; Platinum; Stomach Neoplasms; Thioredoxin Reductase 1 | 2022 |
The Treatment of Human Colon Xenografts Tumor in Mice with Platinum Nanosphere-5-Fluorouracil-Bovine Albumin.
Topics: Animals; Cattle; Colon; Fluorouracil; Heterografts; Humans; Mice; Nanospheres; Platinum; Serum Albumin, Bovine | 2022 |
Bladder preservation in older adults with muscle-invasive bladder cancer: A retrospective study with concurrent chemotherapy and twice-daily hypofractionated radiotherapy schedule.
Topics: Aged; Combined Modality Therapy; Cystectomy; Fluorouracil; Humans; Muscles; Neoplasm Invasiveness; Organ Sparing Treatments; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma.
Topics: Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local; Platinum; Radiotherapy, Conformal; Retrospective Studies | 2022 |
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cost-Benefit Analysis; Delivery of Health Care; Esophageal Neoplasms; Fluorouracil; Humans; Paclitaxel; Platinum; Quality-Adjusted Life Years; Trastuzumab | 2022 |
In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Platinum | 2023 |
Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies.
Topics: Antineoplastic Agents; Cyclophosphamide; Environmental Monitoring; Equipment Contamination; Fluorouracil; Gemcitabine; Humans; Occupational Exposure; Pharmacies; Platinum | 2023 |
Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real-world cohort.
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Platinum; Prospective Studies; Retrospective Studies; Stomach Neoplasms | 2023 |
First-line cetuximab + platinum-based therapy for recurrent/metastatic head and neck squamous cell carcinoma: A real-world observational study-ENCORE.
Topics: Carboplatin; Cetuximab; Cisplatin; Fluorouracil; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Platinum; Prospective Studies; Squamous Cell Carcinoma of Head and Neck | 2023 |